Phage therapy program
SNIPR Biome
| Status | Provider-listed inquiry route |
|---|---|
| Type | Company |
| Location | Copenhagen; Denmark |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Official expanded-access requests to access@sniprbiome.com require a US-based patient and US-licensed, US-based physician. Company reports first patient in Phase 2 portion September 17, 2026. |
|---|---|
| Areas of work | Engineered CRISPR/phage programs; SNIPR001 targets E. coli, including hematologic malignancy/transplant infection-risk research. |
| International access | Published expanded-access policy is US-only; a European expanded-access route was not established. |
What to confirm
- Danish headquarters does not imply access for European patients.
- Protocol recruitment and expanded access have different eligibility.
Related studies(2)
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
Completed
Recorded program–study link. Website
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
Recruiting
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- SNIPR Biome expanded access
- SNIPR Biome home/news
- ClinicalTrials.gov NCT06938867
- ClinicalTrials.gov NCT05277350
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | eu-snipr-biome |
|---|